Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925544 · ClinicalTrials.gov registry record · Phase 2
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
A Phase 2 study of Nasopharyngeal Cancer and Epstein-Barr Virus Related Carcinoma, sponsored by Stanford University.
- Active
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT04925544: Active Phase 2 study of Nasopharyngeal Cancer and Epstein-Barr Virus Related Carcinoma, sponsored by Stanford University.
NCT04925544 is a Phase 2 study of Nasopharyngeal Cancer and Epstein-Barr Virus Related Carcinoma that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 13 participants, below the 183-participant average among 4 other Nasopharyngeal Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04925544, a Phase 2 study of Nasopharyngeal Cancer and Epstein-Barr Virus Related Carcinoma, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available
Primary Outcome
Response rate to VK 2019 in EBV related NPC subjects will be assessed using RECIST v 1.1 criteria. Response Evaluable Subjects: All treated subjects with measurable disease at baseline and one of the following: 1) at least one post dose tumor assessment, 2) discontinuation prior to the first efficacy assessment due to clinical disease progression or toxicity or 3) death either on treatment or within 28 days of last VK 2019 dose.
Conditions Studied
Interventions
- DRUG VK-2019
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2027-06-17 |
| Phase | Phase 2 |
What the registry record for NCT04925544 still lists
NCT04925544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 183-participant average among 4 other Nasopharyngeal Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Nasopharyngeal Cancer appearing as the primary indexed condition, and to 1 intervention - of which VK-2019 is the first listed.
NCT04925544 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04925544 about?
NCT04925544 is a clinical study titled "Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies". To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available
What is the current status of trial NCT04925544?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2022-01-25. Estimated completion is 2027-06-17.
What conditions does trial NCT04925544 study?
This clinical trial studies the following conditions: Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma.
What interventions are being tested in trial NCT04925544?
The interventions under investigation include: VK-2019 (DRUG).
Who is sponsoring clinical trial NCT04925544?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04925544 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasopharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
RECRUITING · NA
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RECRUITING · Phase 1
-
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI